EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
Edinburgh and Cambridge, UK, – Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA at Independent Non-Executive
NodThera Announces First Patients Dosed in a Phase Ib/IIa Cardiovascular Risk Trial of NLRP3 Inflammasome Inhibitor NT-0796
BOSTON, MA, – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces that the first patients have been
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
Compact, single-use, on-body injector designed to enhance the patient experience of administering EMPAVELI® (pegcetacoplan) WALTHAM, Mass., – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S.
Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR-T Cell Therapy LEU011
London, UK – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using
Mironid Extends Series A Round Raising £35 Million to Date for Development of First-In-Class Small Molecules to Treat Life-Threatening Hereditary Kidney Disease
Glasgow, Scotland – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney
Nyra Medical names Lori Chmura as Chief Executive Officer
ATLANTA, GA – Nyra Medical, an innovative medical device company developing a next generation transcatheter mitral valve repair technology, announced the appointment of Lori Chmura as Chief Executive
NodThera is First To Demonstrate Reduction in Neuroinflammation in the Clinic With Brain Penetrant NLRP3 Inflammasome Inhibitor
– NT-0796 demonstrates reduction of multiple neuroinflammatory and inflammatory biomarkers in plasma and CSF of elderly volunteers in just 7 days – Individuals with the
NodThera Announces Positive First-In-Human Data for Two Brain Penetrant NLRP3 Inflammasome Inhibitors
BOSTON, MA. – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from first-in-human studies